Please wait a minute...
 Home  About the Journal Editorial Board Aims & Scope Peer Review Policy Subscription Contact us
 
Early Edition  //  Current Issue  //  Open Special Issues  //  Archives  //  Most Read  //  Most Downloaded  //  Most Cited
Aging and disease    2017, Vol. 8 Issue (3) : 267-276     DOI: 10.14336/AD.2016.1017
Original Article |
Role of Pro-Inflammatory Cytokines and Vitamin D in Probable Alzheimer's Disease with Depression
Banerjee Anindita1,2, Khemka Vineet Kumar1,2, Roy Debashree2, Dhar Aparajita2, Sinha Roy Tapan Kumar2, Biswas Atanu3, Mukhopadhyay Barun4, Chakrabarti Sasanka1,*
1Department of Biochemistry, ICARE Institute of Medical Sciences and Research, Haldia, India.
2Department of Biochemistry, Institute of Post Graduate Medical Education and Research, Kolkata, India.
3Department of Neurology, Bangur Institute of Neurosciences, Kolkata, India.
4Biological Anthropology Unit, Indian Statistical Institute, Kolkata, India.
Download: PDF(1386 KB)   HTML
Export: BibTeX | EndNote | Reference Manager | ProCite | RefWorks    
Abstract  

Symptoms of depression are present in a significant proportion of Alzheimer's disease (AD) patients. While epidemiological studies have shown a strong association between depression and AD, it has not been established whether depression is a risk factor or merely a co-morbidity of AD. It is also uncertain if depression affects the pathogenesis of AD. In this paper, we address these questions by measuring the serum levels of two common metabolic risk factors of AD and depression, inflammatory cytokines (IL 6 and TNF alpha) and serum 25-hydroxyvitamin D, in a case-control study. We measured the serum levels of IL 6, TNF α and 25-hydroxyvitamin D in age-matched healthy controls (n= 60) and in AD patients without depression (n=26) or AD patients with depression (n=34), and statistically analyzed the changes in these parameters among different groups under this study. Our results show that in AD there is a significant increase in IL 6 and TNF α and a marked decrease in 25-hydroxyvitamin D in the peripheral circulation compared to age-matched healthy controls. Furthermore, AD patients with depression have even significantly higher levels of IL 6 or TNF α and a lower level of 25-hydroxyvitamin D in circulation than in AD patients without depression. We also found a strong statistical correlation between the disease severity and the serum levels of IL 6, TNF α and 25-hydroxyvitamin D in AD patients with depression. These results suggest that altered circulating levels of common metabolic risk factors lead to the co-existence of depression with AD in many patients, and when they co-exist, the depression presumably affects the severity of AD presentations through more aggravated changes in these risk factors.

Keywords IL 6      TNF α      25-Hydroxyvitamin D      Neurodegeneration      Amyloid beta peptide     
Corresponding Authors: Chakrabarti Sasanka   
About author:

These authors contributed equally to this work

Issue Date: 01 June 2017
Service
E-mail this article
E-mail Alert
RSS
Articles by authors
Banerjee Anindita
Khemka Vineet Kumar
Roy Debashree
Dhar Aparajita
Sinha Roy Tapan Kumar
Biswas Atanu
Mukhopadhyay Barun
Chakrabarti Sasanka
Cite this article:   
Banerjee Anindita,Khemka Vineet Kumar,Roy Debashree, et al. Role of Pro-Inflammatory Cytokines and Vitamin D in Probable Alzheimer's Disease with Depression[J]. Aging and disease, 2017, 8(3): 267-276.
URL:  
http://www.aginganddisease.org/EN/10.14336/AD.2016.1017     OR     http://www.aginganddisease.org/EN/Y2017/V8/I3/267
Control
(n = 60)
AD with depression
(n = 34)
AD without depression
(n = 26)
Age (in years)71.95 ± 6.2770.20 ± 5.1769.28 ± 4.67
Sex (M/F)31/2918/1614/12
BMI (kg/m2)22.03 ± 1.3921.66 ± 1.0022.42± 0.88
Glucose (mg/dl)88.13 ± 11.6489.10 ± 11.3684.22 ± 12.48
Cholesterol (mg/dl)174.70 ± 16.49213.30 ± 23.17 *203.8 ± 28.32*
Table 1  Demographic and biochemical profile of the subjects
Figure 1.  Serum levels of IL 6, TNF α and 25-hydroxyvitamin D (25 OH vitamin D) in AD subjects

Values are expressed as the means ± SD for the number of cases in each group of subjects. Statistically significant, p<0.0001 AD vs. Control.

Figure 2.  Serum levels of IL 6, TNF α, 25-hydroxyvitamin D (25OH vitamin D) and MMSE in AD subjects with depression (AD with dep) and without depression (AD without dep)

Box and Whisker plots represent median, upper median, lower median, and minimum to maximum range of serum IL 6 (A), TNF α (B) and 25-hydroxyvitamin D (C) while Bar diagram represents mean MMSE (D) among AD subjects with and without depression. Values expressed as the means ± SD are: IL 6 (pg/ml) 10.47±4.18 (AD with depression), 4.56±1.20 (AD without depression); TNFα (pg/ml) 16.84±3.88 (AD with depression), 13.48±2.92 (AD without depression); 25-hydroxyvitamin D (ng/ml) 10.22 ± 3.22 (AD with depression), 15.61 ± 4.64 (AD without depression); MMSE 10.9±4.38 (AD with depression), 19.15±1.46 (AD without depression). Statistically significant difference, p < 0.001, AD subjects with depression versus AD subjects without depression.

Figure 3.  Correlation between MMSE scores and serum levels of 25-hydroxyviamin D (25 OH vitamin D) or IL 6 orTNF α in AD with or without depression. XY scatter plots are shown between MMSE scores and serum levels of 25-hydroxyvitamin D (A) or IL 6 (B) or TNF α (C) in AD subjects with depression or serum levels of 25-hydroxyvitamin D (D) or IL 6 (E) or TNF α (F) in AD subjects without depression. The degree and nature of correlation between the MMSE score and the serum parameter in AD patients is given by the value of r (correlation coefficient) as explained in the methods. A value of p < 0.05 was considered as statistically significant.
Figure 4.  XY scatter plots between serum levels of 25-hydroxyvitamin D (25 OH Vitamin D) and IL 6 or TNF α in AD with or without depression. The degree and nature of correlation between the MMSE score and the serum parameter in AD patients is given by the value of r (correlation coefficient) as explained in the methods. A value of p < 0.05 was considered as statistically significant.
[1] Ritchie K, Lovestone S (2002). The dementias. Lancet, 360: 1759-1766.
[2] Price DL, Sisodia SS (1998). Mutant genes in familial Alzheimer’s disease and transgenic models. Annu Rev Neurosci, 21: 479-505.
[3] Reitz C, Brayne C, Mayeux R (2011). Epidemiology of Alzheimer disease. Nat Rev Neurol, 7: 137-152.
[4] Swerdlow RH (2007). Pathogenesis of Alzheimer's disease. Clin Interv Aging, 2:347-359.
[5] Wyss-Coray T, Rogers J (2012). Inflammation in Alzheimer disease-a brief review of the basic science and clinical literature. Cold Spring Harb Perspect Med, 2: a006346.
[6] Sultana R, Butterfield DA (2010). Role of oxidative stress in the progression of Alzheimer’s disease. J Alzheimers Dis, 19: 341-353.
[7] Sesti F (2016). Oxidation of K(+) channels in aging and neurodegeneration. Aging Dis, 7: 130-135.
[8] Onyango IG, Dennis J, Khan SM (2016). Mitochondrial dysfunction in Alzheimer's disease and the rationale for bioenergetics based therapies. Aging Dis, 7: 201-214.
[9] Rudy CC, Hunsberger HC, Weitzner DS, Reed MN (2015). The role of the tripartite glutamatergic synapse in the pathophysiology of Alzheimer's disease. Aging Dis, 6:131-148.
[10] Hoppe JB, Salbego CG, Cimarosti H (2015). SUMOylation: Novel neuroprotective approach for Alzheimer's disease? Aging Dis, 6: 322-330.
[11] Musiek ES, Holtzman DM (2015). Three dimensions of the amyloid hypothesis: time, space and 'wingmen'. Nat Neurosci, 18: 800-806.
[12] Chakrabarti S, Khemka VK, Banerjee A, Chatterjee G, Ganguly A, Biswas A (2015). Metabolic risk factors of sporadic Alzheimer's disease: Implications in the pathology, pathogenesis and treatment. Aging Dis, 6: 282-299.
[13] Yates D, McLoughlin DM (2008). The molecular pathology of Alzheimer’s disease. Psychiatry, 71: 1-5.
[14] Duarte JM (2015). Metabolic associations associated to brain dysfunction in diabetes. Aging Dis, 6: 304-321.
[15] Chakrabarti S, Mohanakumar KP (2016). Aging and neurodegeneration: A tangle of models and mechanisms. Aging Dis, 7: 111-113.
[16] Cerejeira J, Lagarto L, Mukaetova-Ladinska EB (2012). Behavioral and psychological symptoms of dementia. Front Neurol, 3: 73.
[17] Brommelhoff JA, Gatz M, Johansson B, McArdle JJ, Fratiglioni L, Pedersen NL (2009). Depression as a risk factor or prodromal feature for dementia? Findings in a population based sample of Swedish twins. Psychol Aging, 24: 373-384.
[18] Berger AK, Fratiglioni L, Forsell Y, Winblad B, Backman L (1999). The occurrence of depressive symptoms in the preclinical phase of AD: A population-based study. Neurology, 53: 1998-2002.
[19] Yaffe K, Blackwell T, Gore R, Sands L, Reus V, Browner WS (1999). Depressive symptoms and cognitive decline in non demented elderly women: A prospective study. Arch Gen Psychiatry, 56: 425-430.
[20] Diniz BS, Butters MA, Albert SM, Dew MA, Reynolds CF3rd (2013). Late-life depression and risk of vascular dementia and Alzheimer's disease: systematic review and meta-analysis of community-based cohort studies. Br J Psychiatry, 202:329-335.
[21] Annweiler C, Llewellyn DJ, Beauchet O (2013). Low serum vitamin D concentrations in Alzheimer's disease: a systematic review and meta-analysis. J Alzheimers Dis, 33:659-674.
[22] Llewellyn DJ, Langa KM, Lang IA (2009). Serum 25-hydroxyvitamin D concentration and cognitive impairment. J Geriatr Psychiatry Neurol, 22:188-195.
[23] Knekt P, Saaksjarvi K, Jarvinen R, Marniemi J, Monnisto S, Kanerva N, Heliovaara M (2014). Serum 25-hydroxyvitamin d concentration and risk of dementia. Epidemiology, 25: 799-804.
[24] Morley JE (2014). Dementia. Does vitamin D modulate cognition? Nat Rev Neurol, 10:613-614.
[25] Polak MA, Houghton LA, Reeder AI, Harper MJ, Conner TS (2014). Serum 25-hydroxyvitamin D concentrations and depressive symptoms among young adult men and women. Nutrients, 6: 4720-730.
[26] Milaneschi Y, Hoogendijk W, Lips P, Heijboer AC, Schoevers R, van Hemert AM, Beekman AT, Smit JH, Penninx BW (2014). The association between low vitamin D and depressive disorders. Mol Psychiatry, 19: 444-451.
[27] Alvarez XA, Franco A, Fernandez-Novoa L, Cacabelos R (1996). Blood levels of histamine, IL-1beta, and TNF-alpha in patients with mild to moderate Alzheimer disease. Mol Chem Neuropathol, 29: 237-252.
[28] Humpel C, Hochstrasser T (2011). Cerebrospinal fluid and blood biomarkers in Alzheimer’s disease. World J Psychiatry, 1: 8-18.
[29] Swardfager W, Lanctot K, Rothenburg L, Wong A, Capell J, Hermann NA (2010). A meta-analysis of cytokines in Alzheimer’s disease. Biol Psychiatry, 68: 930-941.
[30] Vogelzangs N, Duivis HE, Beekman AT, Kluft C, Neuteboom J, Hoogendijk W, Smit JH, de Jonge P, Penninx BW (2012). Association of depressive disorders, depression characteristics and antidepressant medication with inflammation. Transl Psychiatry, 2: e79.
[31] Dowlati Y, Herrmann N, Swardfager W, Liu H, Sham L, Reim EK, Lanctot KL (2010). A meta-analysis of cytokines in major depression. Biol Psychiatry, 67: 446-457.
[32] Balion C, Griffith LE, Strifler L, et al (2012). Vitamin D, cognition, and dementia: a systematic review and meta-analysis. Neurology, 79: 1397-1405.
[33] Banerjee A, Khemka VK, Ganguly A, Roy D, Ganguly U, Chakrabarti S (2015). Vitamin D and Alzheimer's Disease: Neurocognition to Therapeutics. Int J Alzheimers Dis, 2015: 192747.
[34] Dantzer R, O'Connor JC, Freund GG, Johnson RW, Kelley KW (2008). From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci, 9:46-56.
[35] Lim A, Krajina K, Marsland AL (2013). Peripheral inflammation and cognitive aging. Mod Trends Pharmacopsychiatri, 28: 175-187.
[36] Ownby RL, Crocco E, Acevedo A, John V, Loewenstein D (2006). Depression and risk for Alzheimer disease: systematic review, meta-analysis, and meta regression analysis. Arch Gen Psychiatry, 63:530-538.
[37] Van der Mussele S, Fransen E, Struyfs H, Luyckx J, Mariën P, Saerens J, Somers N, Goeman J, De Deyn PP, Engelborghs S (2014). Depression in mild cognitive impairment is associated with progression to Alzheimer's disease: a longitudinal study. J Alzheimers Dis, 42: 1239-1250.
[38] Palmer K, Di Iulio F, Varsi AE, Gianni W, Sancesario G, Caltagirone C, Spalletta G (2010). Neuropsychiatric predictors of progression from amnestic-mild cognitive impairment to Alzheimer's disease: the role of depression and apathy. J Alzheimers Dis, 20: 175-183.
[39] Hurley LL, Tizabi Y (2013). Neuroinflammation, neurodegeneration, and depression. Neurotox Res, 23: 131-144.
[40] Stockmeier CA, Mahajan GJ, Konick LC, Overholser JC, Jurjus GJ, Meltzer HY, Uylings HB, Friedman L, Rajkowska G (2004). Cellular changes in the postmortem hippocampus in major depression. Biol Psychiatry, 56: 640-650.
[41] Swaab DF, Bao AM, Lucassen PJ (2005). The stress system in the human brain in depression and neurodegeneration. Ageing Res Rev, 4:141-194.
[42] Wuwongse S, Chang RC, Law AC (2010). The putative neurodegenerative links between depression and Alzheimer’s disease. Prog Neurobiol, 91: 362-375.
[43] Chi S, Wang C, Jiang T, Zhu XC, Yu JT, Tan L (2015). The prevalence of depression in Alzheimer's disease: a systematic review and meta-analysis. Curr Alzheimer Res, 12:189-198.
[44] Khemka VK, Ganguly A, Bagchi D, et al (2014). Raised serum proinflammatory cytokines in Alzheimer's disease with depression. Aging Dis, 5:170-176.
[45] Lanzrein AS, Johnston CM, Perry VH, Jobst KA, King EM, Smith AD (1998). Longitudinal study of inflammatory factors in serum, cerebrospinal fluid, and brain tissue in Alzheimer disease: interleukin-1beta, interleukin-6, interleukin-1 receptor antagonist, tumor necrosis factor-alpha, the soluble tumor necrosis factor receptors I and II, and alpha1-antichymotrypsin. Alzheimer Dis Assoc Disord, 12: 215-227.
[46] Bermejo P, Martin-Aragon S, Benedi J, Susin C, Felici E, Gil P, Ribera JM, Villar AM (2008). Differences of peripheral inflammatory markers between mild cognitive impairment and Alzheimer's disease. Immunol Lett, 117: 198-202.
[47] Paganelli R, Di Iorio A, Patricelli L, Ripani F, Sparvieri E, Faricelli R, Iarlori C, Porreca E, Di Gioacchino M, Abate G (2002). Proinflammatory cytokines in sera of elderly patients with dementia: levels in vascular injury are higher than those of mild-moderate Alzheimer’s disease patients. Exp Gerontol, 37:257-263.
[48] Felger JC, Lotrich FE (2013). Inflammatory cytokines in depression: neurobiological mechanisms and therapeutic implications. Neuroscience, 246:199-229.
[49] Weisman D, Hakimian E, Ho GJ (2006). Interleukins, inflammation, and mechanisms of Alzheimer’s disease. Vitam Horm, 74:505-530.
[50] Maier SF (2003). Bi-directional immune-brain communication: implications for understanding stress, pain, and cognition. Brain Behav Immun, 17: 69-85.
[51] Wilson CJ, Finch CE, Cohen HJ (2002). Cytokines and cognition - The case for head-to-toe inflammatory paradigm. J Am Geriatr Soc, 50: 2041-2056
[52] Anisman H (2009). Cascading effects of stressors and inflammatory immune system activation: implications for major depressive disorder. J Psychiatry Neurosci, 34: 4-20.
[53] Ito S, Ohtsuki S, Nezu Y, Koitabashi Y, Murata S, Terasaki T (2011). 1α,25-dihydroxyvitamin D3 enhances cerebral clearance of human amyloid-β peptide (1-40) from mouse brain across the blood-brain barrier. Fluids Barriers CNS, 8: 20.
[54] Brown J, Bianco JI, McGrath JJ, Eyles DW (2003). 1,25-Dihydroxyvitamin D3 induces nerve growth factor, promotes neurite outgrowth and inhibits mitosis in embryonic rat hippocampal neurons. Neurosci Lett, 343: 139-143.
[55] Masoumi A, Goldenson B, Ghirmai S, Avagyan H, Zaghi J, Abel K, Zheng X, Espinosa-Jeffrey A, Mahanian M, Liu PT, Hewison M, Mizwickie M, Cashman J, Fiala M (2009). 1α,25-dihydroxyvitamin D3 interacts with curcuminoids to stimulate amyloid-β clearance by macrophages of Alzheimer’s disease patients. J Alzheimers Dis, 17: 703-717.
[56] Zhang Y, Leung DY, Richers BN, Liu Y, Remigio LK, Riches DW, Goleva E (2012). Vitamin D inhibits monocyte/macrophage proinflammatory cytokine production by targeting MAPK phosphatase-1. J Immunol, 188: 2127-2135.
[57] Harant H, Wolff B, Lindley IJ (1998). 1alpha, 25-dihydroxyvitaminD3 decreases DNA binding of nuclear factor - kappa B in human fibroblasts. FEBS Lett, 436: 329-334.
[1] Antonina Luca, Carmela Calandra, Maria Luca. Molecular Bases of Alzheimer’s Disease and Neurodegeneration: The Role of Neuroglia[J]. Aging and disease, 2018, 9(6): 1134-1152.
[2] Jue Wang,Bin Cao,Haiping Zhao,Juan Feng. Emerging Roles of Ganoderma Lucidum in Anti-Aging[J]. A&D, 2017, 8(6): 691-707.
[3] Murat Serdar Gurses,Mustafa Numan Ural,Mehmet Akif Gulec,Omer Akyol,Sumeyya Akyol. Pathophysiological Function of ADAMTS Enzymes on Molecular Mechanism of Alzheimer’s Disease[J]. A&D, 2016, 7(4): 479-490.
[4] Daniel O. Claassen,David G. Dobolyi,David A. Isaacs,Olivia C. Roman,Joshua Herb,Scott A. Wylie,Joseph S. Neimat,Manus J. Donahue,Peter Hedera,David H. Zald,Bennett A. Landman,Aaron B. Bowman,Benoit M. Dawant,Swati Rane. Linear and Curvilinear Trajectories of Cortical Loss with Advancing Age and Disease Duration in Parkinson’s Disease[J]. A&D, 2016, 7(3): 220-229.
[5] Sasanka Chakrabarti,Kochupurackal P. Mohanakumar. Aging and Neurodegeneration: A Tangle of Models and Mechanisms[J]. A&D, 2016, 7(2): 111-113.
[6] João M N. Duarte. Metabolic Alterations Associated to Brain Dysfunction in Diabetes[J]. A&D, 2015, 6(5): 304-321.
[7] Claudia Rangel-Barajas,Israel Coronel,Benjamín Florán. Dopamine Receptors and Neurodegeneration[J]. A&D, 2015, 6(5): 349-368.
[8] Paul H. Gordon. Amyotrophic Lateral Sclerosis: An update for 2013 Clinical Features, Pathophysiology, Management and Therapeutic Trials[J]. Aging and Disease, 2013, 4(5): 295-310.
[9] Jose L. Labandeira-Garcia,Jannette Rodriguez-Pallares,Begoña Villar-Cheda,Ana I. Rodríguez-Perez,Pablo Garrido-Gil,Maria J. Guerra. Aging, Angiotensin System and Dopaminergic Degeneration in the Substantia Nigra[J]. Aging and Disease, 2011, 2(3): 257-274.
[10] Bharathi Hattiangady,Ramkumar Kuruba,Ashok K. Shetty. Acute Seizures in Old Age Leads to a Greater Loss of CA1 Pyramidal Neurons, an Increased Propensity for Developing Chronic TLE and Severe Cognitive Dysfunction[J]. Aging and Disease, 2011, 2(1): 1-18.
[11] Adam D. Bachstetter,Linda J. Van Eldik. The p38 MAP Kinase Family as Regulators of Proinflammatory Cytokine Production in Degenerative Diseases of the CNS[J]. Aging and Disease, 2010, 1(3): 199-211.
[12] Lindsay C. Reese,Giulio Taglialatela. Neuroimmunomodulation by Calcineurin in Aging and Alzheimer’s Disease[J]. Aging and Disease, 2010, 1(3): 245-253.
[13] Jana Doehner, Irene Knuesel. Reelin-mediated Signaling during Normal and Pathological Forms of Aging[J]. A&D, 2010, 1(1): 12-29.
Viewed
Full text


Abstract

Cited

  Shared   
Copyright © 2014 Aging and Disease, All Rights Reserved.
Address: Aging and Disease Editorial Office 3400 Camp Bowie Boulevard Fort Worth, TX76106 USA
Fax: (817) 735-0408 E-mail: editorial@aginganddisease.org
Powered by Beijing Magtech Co. Ltd